EASL Recommendations on Treatment of Hepatitis C 2016.
D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005060:Europe; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D018936:Hepatitis C Antigens / Q000097:blood; D006801:Humans; D012367:RNA, Viral / Q000097:blood; D012720:Severity of Illness Index; D000072230:Sustained Virologic Response; D014758:Viral Core Proteins / Q000097:blood
D000998:Antiviral Agents; D018936:Hepatitis C Antigens; D012367:RNA, Viral; D014758:Viral Core Proteins